S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in

Alpine Immune Sciences Stock Forecast, Price & News

+0.31 (+2.72 %)
(As of 02/26/2021 12:00 AM ET)
Today's Range
Now: $11.72
50-Day Range
MA: $12.57
52-Week Range
Now: $11.72
Volume289,938 shs
Average Volume129,483 shs
Market Capitalization$278.97 million
P/E RatioN/A
Dividend YieldN/A
Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.
Alpine Immune Sciences logo


Is ALPN A Good Stock To Buy Now?
December 12, 2020 |  finance.yahoo.com
Alpine (ALPN) Looks Good: Stock Adds 7.8% in Session
December 8, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ALPN
Year FoundedN/A



Sales & Book Value

Annual Sales$1.74 million
Book Value$1.59 per share


Net Income$-41,850,000.00
Net Margins-606.16%


Market Cap$278.97 million
Next Earnings Date3/29/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.81 out of 5 stars

Medical Sector

139th out of 1,962 stocks

Pharmaceutical Preparations Industry

65th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
+0.31 (+2.72 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALPN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions

Is Alpine Immune Sciences a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Alpine Immune Sciences stock.
View analyst ratings for Alpine Immune Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than Alpine Immune Sciences?

Wall Street analysts have given Alpine Immune Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Alpine Immune Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Alpine Immune Sciences' next earnings date?

Alpine Immune Sciences is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for Alpine Immune Sciences

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced its quarterly earnings results on Tuesday, November, 17th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.05. The biotechnology company earned $1.91 million during the quarter, compared to the consensus estimate of $4.80 million. Alpine Immune Sciences had a negative net margin of 606.16% and a negative trailing twelve-month return on equity of 80.38%.
View Alpine Immune Sciences' earnings history

How has Alpine Immune Sciences' stock price been impacted by COVID-19 (Coronavirus)?

Alpine Immune Sciences' stock was trading at $2.91 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ALPN shares have increased by 302.7% and is now trading at $11.72.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ALPN?

6 brokerages have issued 1 year price objectives for Alpine Immune Sciences' stock. Their forecasts range from $17.00 to $22.00. On average, they expect Alpine Immune Sciences' stock price to reach $19.40 in the next year. This suggests a possible upside of 65.5% from the stock's current price.
View analysts' price targets for Alpine Immune Sciences
or view top-rated stocks among Wall Street analysts.

Who are Alpine Immune Sciences' key executives?

Alpine Immune Sciences' management team includes the following people:
  • Dr. Mitchell H. Gold M.D., Exec. Chairman & CEO (Age 53, Pay $703.25k)
  • Dr. Stanford Peng, Pres and Head of R&D (Age 50, Pay $650.83k)
  • Mr. Paul Rickey, Sr. VP, CFO & Corp. Sec. (Age 42, Pay $489.79k)
  • Dr. Wayne R. Gombotz, Chief Technology Officer (Age 62)
  • Dr. Jan L. Hillson M.D., Sr. VP of Clinical Devel. (Age 68)
  • Dr. Remy Durand Ph.D., Chief Bus. Officer
  • Dr. Pamela Holland Ph.D., Sr. VP of Research

Who are some of Alpine Immune Sciences' key competitors?

What other stocks do shareholders of Alpine Immune Sciences own?

What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

Who are Alpine Immune Sciences' major shareholders?

Alpine Immune Sciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (12.90%), Avidity Partners Management LP (5.24%), Renaissance Technologies LLC (1.93%), Samsara BioCapital LLC (1.68%), Morgan Stanley (1.59%) and Caas Capital Management LP (0.62%). Company insiders that own Alpine Immune Sciences stock include James Paul Rickey, Orbimed Advisors Llc and Robert E Conway.
View institutional ownership trends for Alpine Immune Sciences

Which institutional investors are selling Alpine Immune Sciences stock?

ALPN stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Samsara BioCapital LLC, and BlackRock Inc..
View insider buying and selling activity for Alpine Immune Sciences
or view top insider-selling stocks.

Which institutional investors are buying Alpine Immune Sciences stock?

ALPN stock was bought by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Morgan Stanley, Caas Capital Management LP, Pura Vida Investments LLC, ExodusPoint Capital Management LP, Renaissance Technologies LLC, Vista Capital Partners Inc., and Bank of New York Mellon Corp. Company insiders that have bought Alpine Immune Sciences stock in the last two years include James Paul Rickey, and Robert E Conway.
View insider buying and selling activity for Alpine Immune Sciences
or or view top insider-buying stocks.

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alpine Immune Sciences' stock price today?

One share of ALPN stock can currently be purchased for approximately $11.72.

How much money does Alpine Immune Sciences make?

Alpine Immune Sciences has a market capitalization of $278.97 million and generates $1.74 million in revenue each year. The biotechnology company earns $-41,850,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis.

How many employees does Alpine Immune Sciences have?

Alpine Immune Sciences employs 53 workers across the globe.

What is Alpine Immune Sciences' official website?

The official website for Alpine Immune Sciences is www.alpineimmunesciences.com.

Where are Alpine Immune Sciences' headquarters?

Alpine Immune Sciences is headquartered at 188 East Blaine Street Suite 200, Seattle WA, 98102.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]

This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.